Morey Trevor M, Winick-Ng Warren, Seah Claudia, Rylett R Jane
Molecular Medicine Research Laboratories, Robarts Research Institute, University of Western Ontario, London, ON, Canada.
Department of Physiology and Pharmacology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada.
Front Mol Neurosci. 2017 Dec 12;10:415. doi: 10.3389/fnmol.2017.00415. eCollection 2017.
Choline acetyltransferase (ChAT) synthesizes the neurotransmitter acetylcholine in cholinergic neurons, and mutations of this enzyme are linked to the neuromuscular disorder congenital myasthenic syndrome (CMS). One CMS-related mutation, V18M, reduces ChAT enzyme activity and cellular protein levels, and is located within a highly-conserved N-terminal proline-rich motif at residues PKLPPP. We showed previously that disruption of this proline-rich motif by either proline-to-alanine mutation (P17A/P19A) or mutation of residue Val (V18M) enhances ubiquitination and degradation of these mutant ChAT proteins expressed in cholinergic SN56 cells by an unknown mechanism. In this study, using proximity-dependent biotin identification (BioID), co-immunoprecipitation and proximity-ligation assay (PLA), we identified the heat shock proteins (HSPs) HSC/HSP70 and HSP90 as novel ChAT protein-interactors. These molecular chaperones are well-known for promoting the folding and stabilization of cellular proteins. Thus, we found that inhibition of HSPs by treatment of cells with either the HSC/HSP70 inhibitors 2-phenylethynesulfonamide (PES) or VER-155008, or the HSP90 inhibitor 17-AAG reduced cellular ChAT activity and solubility, and enhanced the ubiquitination and proteasome-dependent loss of ChAT protein. Importantly, the effects of HSP inhibition were greater for mutant ChAT proteins (P17A/P19A-ChAT and CMS-related V18M- and A513T-ChAT) compared to wild-type ChAT. HSPs can promote ubiquitination and degradation of terminally misfolded proteins through cooperative interaction with the E3 ubiquitin ligase CHIP/Stub1, and while we show that ChAT interacts with CHIP , siRNA-mediated knock-down of CHIP had no effect on either wild-type or mutant ChAT protein levels. However, inhibition of the endoplasmic reticulum (ER)- and HSP-associated co-chaperone p97/VCP prevented degradation of ubiquitinated ChAT. Together, these results identify novel mechanisms for the functional regulation of wild-type and CMS-related mutant ChAT by pro-stabilizing HSPs and the pro-degradative co-chaperone p97/VCP that may have broader implications for ChAT function during cellular stress and disease.
胆碱乙酰转移酶(ChAT)在胆碱能神经元中合成神经递质乙酰胆碱,该酶的突变与神经肌肉疾病先天性肌无力综合征(CMS)相关。一种与CMS相关的突变V18M,降低了ChAT酶活性和细胞蛋白水平,且位于高度保守的N端富含脯氨酸的基序(PKLPPP残基处)内。我们之前表明,通过脯氨酸到丙氨酸的突变(P17A/P19A)或缬氨酸残基的突变(V18M)破坏这个富含脯氨酸的基序,会通过未知机制增强在胆碱能SN56细胞中表达的这些突变ChAT蛋白的泛素化和降解。在本研究中,我们使用邻近依赖性生物素识别(BioID)、免疫共沉淀和邻近连接分析(PLA),鉴定了热休克蛋白(HSPs)HSC/HSP70和HSP90为新型ChAT蛋白相互作用分子。这些分子伴侣以促进细胞蛋白的折叠和稳定而闻名。因此,我们发现用HSC/HSP70抑制剂2-苯乙炔磺酰胺(PES)或VER-155008,或HSP90抑制剂17-AAG处理细胞来抑制HSPs,会降低细胞ChAT活性和溶解度,并增强ChAT蛋白的泛素化和蛋白酶体依赖性损失。重要的是,与野生型ChAT相比,HSP抑制对突变ChAT蛋白(P17A/P19A-ChAT以及与CMS相关的V18M-和A513T-ChAT)的影响更大。HSPs可以通过与E3泛素连接酶CHIP/Stub1协同相互作用来促进末端错误折叠蛋白的泛素化和降解,虽然我们表明ChAT与CHIP相互作用,但siRNA介导的CHIP敲低对野生型或突变型ChAT蛋白水平均无影响。然而,抑制内质网(ER)和HSP相关的共伴侣p97/VCP可防止泛素化ChAT的降解。总之,这些结果确定了通过促进稳定的HSPs和促降解共伴侣p97/VCP对野生型和与CMS相关的突变型ChAT进行功能调节的新机制,这可能对细胞应激和疾病期间的ChAT功能具有更广泛的影响。